180 related articles for article (PubMed ID: 15777350)
1. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
Voskaridou E; Terpos E
Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
[No Abstract] [Full Text] [Related]
2. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
3. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
Al-Fakhri N; Hofbauer LC; Preissner KT; Franke FE; Schoppet M
Thromb Haemost; 2005 Dec; 94(6):1335-7. PubMed ID: 16411417
[No Abstract] [Full Text] [Related]
4. Osteoclast differentiation and activation.
Boyle WJ; Simonet WS; Lacey DL
Nature; 2003 May; 423(6937):337-42. PubMed ID: 12748652
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
6. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
Ashcroft AJ; Carding SR
Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
[No Abstract] [Full Text] [Related]
7. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
8. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
9. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
10. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
11. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
12. [[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin?].
Bénard J
Bull Cancer; 2000 Sep; 87(9):623-4. PubMed ID: 11184451
[No Abstract] [Full Text] [Related]
13. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporosis].
Chaki O
Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
[No Abstract] [Full Text] [Related]
15. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis.
Voskaridou E; Stoupa E; Antoniadou L; Premetis E; Konstantopoulos K; Papassotiriou I; Terpos E
Haematologica; 2006 Jun; 91(6):813-6. PubMed ID: 16704959
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid.
Hofbauer LC; Cepok S; Hemmer B
Acta Neuropathol; 2004 Jun; 107(6):575-7, author reply 578. PubMed ID: 15106011
[No Abstract] [Full Text] [Related]
17. Genetic regulation of osteoclast development and function.
Teitelbaum SL; Ross FP
Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
[TBL] [Abstract][Full Text] [Related]
18. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
19. [Osteoporosis induced by immunosuppressant].
Fukunaga J; Sugahara T
Nihon Rinsho; 2004 Feb; 62 Suppl 2():740-3. PubMed ID: 15035219
[No Abstract] [Full Text] [Related]
20. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
